Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M2,558Revenue $M2.9Net Margin (%)-3,546.3Z-Score42.6
Enterprise Value $M2,419EPS $-0.7Operating Margin %-3,802.1F-Score2
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-3,546.3Higher ROA y-yN
Price/Book11.610-y EBITDA Growth Rate %0Quick Ratio13.1Cash flow > EarningsY
Price/Sales3,3375-y EBITDA Growth Rate %0Current Ratio13.1Lower Leverage y-yN
Price/Cash Flow10.0y-y EBITDA Growth Rate %0ROA % (ttm)-23.0Higher Current Ratio y-yY
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-27.0Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M76.0ROI % (ttm)-12.8Gross Margin Increase y-yN

Gurus Latest Trades with NBIX

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
NBIXGeorge Soros 2013-09-30 Sold Out -0.03%$10.6 - $16.7
($13.79)
$ 33.66144%Sold Out0
NBIXGeorge Soros 2013-06-30 Buy 0.03%$10.9 - $13.57
($12.28)
$ 33.66174%New holding, 200000 sh.200,000
NBIXJoel Greenblatt 2012-12-31 Sold Out -0.13%$6.88 - $8.66
($7.6)
$ 33.66343%Sold Out0
NBIXJoel Greenblatt 2012-06-30 Add0.03%$6.31 - $8.06
($7.18)
$ 33.66369%Add 23.8%259,903
NBIXGeorge Soros 2012-06-30 Sold Out -0.02%$6.31 - $8.06
($7.18)
$ 33.66369%Sold Out0
NBIXJoel Greenblatt 2012-03-31 Buy 0.15%$7.33 - $9.79
($7.95)
$ 33.66323%New holding, 209930 sh.209,930
NBIXGeorge Soros 2012-03-31 Buy 0.02%$7.33 - $9.79
($7.95)
$ 33.66323%New holding, 150000 sh.150,000
NBIXGeorge Soros 2011-12-31 Sold Out -0.0018%$5.5 - $8.58
($6.76)
$ 33.66398%Sold Out0
NBIXGeorge Soros 2011-09-30 Reduce$5.59 - $8.44
($6.71)
$ 33.66402%Reduce -23.93%17,800
NBIXGeorge Soros 2011-06-30 Add$6.82 - $8.3
($7.54)
$ 33.66346%Add 90.24%23,400
NBIXGeorge Soros 2011-03-31 Add$6.47 - $7.84
($7.2)
$ 33.66368%Add 23%12,300
NBIXGeorge Soros 2010-12-31 Buy $5.99 - $8.53
($7.63)
$ 33.66341%New holding, 10000 sh.10,000
NBIXGeorge Soros 2008-06-30 Sold Out -0.01%$4.28 - $5.86
($5)
$ 33.66573%Sold Out0
NBIXGeorge Soros 2008-03-31 Buy 0.01%$4.51 - $5.58
($5.1)
$ 33.66560%New holding, 21038 sh.21,038
NBIXGeorge Soros 2007-12-31 Sold Out -0.01%$4.4 - $13.02
($9)
$ 33.66274%Sold Out0
NBIXGeorge Soros 2007-09-30 Add$9.69 - $11.88
($10.6)
$ 33.66218%Add 61.87%20,362
NBIXGeorge Soros 2007-06-30 Buy $11.39 - $14.14
($12.4)
$ 33.66172%New holding, 12579 sh.12,579
NBIXGeorge Soros 2006-12-31 Sold Out -0.02%$7.72 - $12.55
($10.2)
$ 33.66230%Sold Out0
NBIXGeorge Soros 2006-09-30 Buy 0.02%$8.91 - $10.93
($10.1)
$ 33.66233%New holding, 35000 sh.35,000
NBIXGeorge Soros 2006-03-31 Buy 0.23%$59.43 - $70.41
($64.8)
$ 33.66-48%New holding, 100000 sh.100,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

NBIX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


NBIX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
OBrien Christopher FlintChief Medical Officer 2015-01-16Sell1,750$30.798.44view
Coughlin Timothy PCFO 2015-01-16Sell1,750$30.818.37view
GORMAN KEVIN CHARLESPresident and CEO 2015-01-16Sell3,750$30.798.44view
Gano KyleChief Business Dev Officer 2015-01-16Sell1,625$30.88.41view
Bozigian Haig P.Chief Development Officer 2015-01-16Sell1,625$30.798.44view
Grigoriadis Dimitri E.Chief Research Officer 2015-01-16Sell1,625$30.778.51view
Grigoriadis Dimitri E.Chief Research Officer 2015-01-13Sell20,000$3011.3view
Gano KyleChief Business Dev Officer 2015-01-13Sell25,000$3011.3view
MITCHELL W THOMASDirector 2015-01-13Sell45,000$30.0711.04view
Coughlin Timothy PCFO 2015-01-12Sell1,750$28.3717.69view

Press Releases about NBIX :

    Quarterly/Annual Reports about NBIX:

    News about NBIX:

    Articles On GuruFocus.com
    Weekly Insider Sells Highlight: ORCL, TWC, FB, NBIX Jan 13 2014 
    5 Strong Healthcare Stocks For 2012 Mar 24 2012 
    Consider These 5 Healthcare Stocks Now Mar 21 2012 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,320 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,400 Shares Mar 02 2011 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Oct 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Jul 29 2010 
    Neurocrine Biosciences Inc. Reports Operating Results (10-Q) Apr 29 2010 
    Neurocrine Biosciences Inc. (NBIX) VP and CFO Timothy P Coughlin sells 12,650 Shares Mar 03 2010 
    Neurocrine Biosciences Inc. (NBIX) President and CEO Kevin Charles Gorman sells 15,609 Shares Mar 03 2010 

    More From Other Websites
    Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic... Jan 20 2015
    Neurocrine Biosciences Announces Oral Presentation of NBI-77860 Clinical Trial Data in Classic... Jan 20 2015
    Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal... Jan 16 2015
    Neurocrine Biosciences Announces Granting of Orphan Drug Status for NBI-77860 in Congenital Adrenal... Jan 16 2015
    US STOCKS-Wall St jumps for 2nd day, helped by economic optimism Jan 08 2015
    US STOCKS-Wall St jumps for 2nd day, helped by economic optimism Jan 08 2015
    US STOCKS-Wall St jumps for 2nd day, helped by economic optimism Jan 08 2015
    US STOCKS-Wall St up more than 1 pct for 2nd day; Fed, ECB lift Jan 08 2015
    US STOCKS-Wall St up more than 1 pct for 2nd day; Fed, ECB lift Jan 08 2015
    NBIX: AbbVie, Neurocrine Report Positive Data With Elagolix In Phase 3 Violet Petal Study Jan 08 2015
    Midday movers: Apple, Ford Motor, Yahoo & more Jan 08 2015
    Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
    Neurocrine Biosciences to Present at the 33rd Annual J.P. Morgan Healthcare Conference Jan 08 2015
    AbbVie, Neurocrine drug successful in endometriosis trial Jan 08 2015
    AbbVie Announces Positive Top-Line Results From Phase 3 Study of Investigational Medicine Elagolix... Jan 08 2015
    What Investors Expect From Neurocrine Biosciences' Next Drug Announcement Jan 02 2015
    ASPX: Auspex Pharma Hits A Homerun In Phase 3 Huntington's Chorea Trial Dec 17 2014
    Neurocrine draws bearish trade Dec 11 2014
    Neurocrine Biosciences Announces Expansion of its Clinical Pipeline Dec 10 2014
    Neurocrine Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference Dec 04 2014

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK